MX9207334A - NUCLEIC ACIDS PEPTIDICS AND PHARMACEUTICAL FORMULATION CONTAINING THEM - Google Patents

NUCLEIC ACIDS PEPTIDICS AND PHARMACEUTICAL FORMULATION CONTAINING THEM

Info

Publication number
MX9207334A
MX9207334A MX9207334A MX9207334A MX9207334A MX 9207334 A MX9207334 A MX 9207334A MX 9207334 A MX9207334 A MX 9207334A MX 9207334 A MX9207334 A MX 9207334A MX 9207334 A MX9207334 A MX 9207334A
Authority
MX
Mexico
Prior art keywords
peptidics
nucleic acids
pharmaceutical formulation
formulation containing
antisensitizers
Prior art date
Application number
MX9207334A
Other languages
Spanish (es)
Inventor
Stephen Andrew Thomson
Stewart Alwyn Noble
Daniel Joseph Ricca
Original Assignee
Glaxo Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Inc filed Critical Glaxo Inc
Publication of MX9207334A publication Critical patent/MX9207334A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C07K14/003—Peptide-nucleic acids (PNAs)
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
    • C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
    • C08G69/10—Alpha-amino-carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a oligómeros de ácidos nucléicos de péptidos y a su uso para afectar material genético, por ejemplo, como triplex o antisensibilizantes en el tratamiento de la enfermedad.The present invention relates to peptide nucleic acid oligomers and their use to affect genetic material, for example, as triplex or antisensitizers in the treatment of disease.

MX9207334A 1991-12-18 1992-12-16 NUCLEIC ACIDS PEPTIDICS AND PHARMACEUTICAL FORMULATION CONTAINING THEM MX9207334A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US80966191A 1991-12-18 1991-12-18

Publications (1)

Publication Number Publication Date
MX9207334A true MX9207334A (en) 1993-08-01

Family

ID=25201908

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9207334A MX9207334A (en) 1991-12-18 1992-12-16 NUCLEIC ACIDS PEPTIDICS AND PHARMACEUTICAL FORMULATION CONTAINING THEM

Country Status (10)

Country Link
EP (1) EP0618923A4 (en)
JP (1) JPH07502509A (en)
AU (2) AU3325493A (en)
CA (1) CA2125966A1 (en)
FI (1) FI942935A (en)
MX (1) MX9207334A (en)
NO (1) NO942327D0 (en)
NZ (1) NZ246473A (en)
WO (1) WO1993012129A1 (en)
ZA (1) ZA929764B (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6228982B1 (en) * 1992-05-22 2001-05-08 Benget Norden Double-stranded peptide nucleic acids
US7223833B1 (en) 1991-05-24 2007-05-29 Isis Pharmaceuticals, Inc. Peptide nucleic acid conjugates
DK51092D0 (en) 1991-05-24 1992-04-15 Ole Buchardt OLIGONUCLEOTIDE ANALOGUE DESCRIBED BY PEN, MONOMERIC SYNTHONES AND PROCEDURES FOR PREPARING THEREOF, AND APPLICATIONS THEREOF
US6451968B1 (en) * 1991-05-24 2002-09-17 Isis Pharmaceuticals, Inc. Peptide nucleic acids
US6441130B1 (en) 1991-05-24 2002-08-27 Isis Pharmaceuticals, Inc. Linked peptide nucleic acids
US6713602B1 (en) 1991-05-24 2004-03-30 Ole Buchardt Synthetic procedures for peptide nucleic acids
US5539082A (en) * 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
DE69232032T3 (en) * 1991-12-24 2012-09-13 Isis Pharmaceutical, Inc. ANTISENSE OLIGONUCLEOTIDE
US5700922A (en) * 1991-12-24 1997-12-23 Isis Pharmaceuticals, Inc. PNA-DNA-PNA chimeric macromolecules
US6277603B1 (en) 1991-12-24 2001-08-21 Isis Pharmaceuticals, Inc. PNA-DNA-PNA chimeric macromolecules
US6350853B1 (en) 1993-04-26 2002-02-26 Peter E. Nielsen Conjugated peptide nucleic acids having enhanced cellular uptake
US5527675A (en) * 1993-08-20 1996-06-18 Millipore Corporation Method for degradation and sequencing of polymers which sequentially eliminate terminal residues
DE4331012A1 (en) * 1993-09-13 1995-03-16 Bayer Ag Nucleic acid-binding oligomers with N-branching for therapy and diagnostics
EP0736027B1 (en) * 1993-12-22 2002-05-29 Perseptive Biosystems, Inc. Guanine synthons for peptide nucleic acid synthesis and method for production
US6133444A (en) * 1993-12-22 2000-10-17 Perseptive Biosystems, Inc. Synthons for the synthesis and deprotection of peptide nucleic acids under mild conditions
DK145493D0 (en) * 1993-12-23 1993-12-23 Dako As ANTIBODY
US5539083A (en) 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
DE4408534A1 (en) * 1994-03-14 1995-09-28 Hoechst Ag Substituted N-ethyl-glycine derivatives for the production of PNA and PNA / DNA hybrids
DE4408531A1 (en) * 1994-03-14 1995-09-28 Hoechst Ag PNA synthesis using an amino protecting group labile to weak acids
DE4408533A1 (en) * 1994-03-14 1995-09-28 Hoechst Ag PNA synthesis using a base-labile amino protecting group
DE4427980A1 (en) * 1994-08-08 1996-02-15 Bayer Ag Nucleic acid binding oligomers for therapy and diagnostics
WO1996011205A1 (en) * 1994-10-06 1996-04-18 Isis Pharmaceuticals, Inc. Peptide nucleic acid conjugates
AU4729796A (en) * 1994-12-28 1996-07-19 Peter E. Nielsen Peptide nucleic acid incorporating a chiral backbone
US6465650B1 (en) 1995-03-13 2002-10-15 Aventis Pharma Deutschland Gmbh Substituted N-ethylglycine derivatives for preparing PNA and PNA/DNA hybrids
WO1996040709A1 (en) * 1995-06-07 1996-12-19 Perseptive Biosystems, Inc. Pna-dna chimeras and pna synthons for their preparation
WO1997014793A1 (en) * 1995-10-20 1997-04-24 Trustees Of Boston University Nucleic acid clamps
DE19653646A1 (en) * 1996-12-20 1998-06-25 Hoechst Ag Substituted purine derivatives, processes for their preparation, agents containing them and their use
US6617422B1 (en) 1997-05-23 2003-09-09 Peter Nielsen Peptide nucleic acid monomers and oligomers
AU8147798A (en) * 1997-06-16 1999-01-04 University Of North Carolina At Chapel Hill, The Peptido oligonucleotides (pons) and their combinatorial libraries
WO2000002864A1 (en) * 1998-07-10 2000-01-20 Martens Juergen Precusors for pna-monomers
US6921812B1 (en) 2001-07-03 2005-07-26 Isis Pharmaceuticals, Inc. Methods of modulating pharmacokinetics of oligonucleotides
HUE033832T2 (en) 2002-11-15 2018-01-29 Idenix Pharmaceuticals Llc 2'-methyl nucleosides in combination with interferon and flaviviridae mutation
WO2007073149A1 (en) 2005-12-22 2007-06-28 Keygene N.V. Alternative nucleotides for improved targeted nucleotide exchange
WO2012113775A1 (en) 2011-02-21 2012-08-30 University Of Zurich Ankyrin g and modulators thereof for the treatment of neurodegenerative disorders
WO2014152054A1 (en) 2013-03-15 2014-09-25 Bio-Rad Laboratories, Inc. Digital assays for mutation detection
WO2018175927A2 (en) * 2017-03-23 2018-09-27 Trucode Gene Repair, Inc. Peptide nucleic acid (pna) monomers with an orthogonally protected ester moiety

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0639582B1 (en) * 1985-03-15 1998-09-16 Antivirals Inc. Polynucleotide assay reagent and method
DK51092D0 (en) * 1991-05-24 1992-04-15 Ole Buchardt OLIGONUCLEOTIDE ANALOGUE DESCRIBED BY PEN, MONOMERIC SYNTHONES AND PROCEDURES FOR PREPARING THEREOF, AND APPLICATIONS THEREOF

Also Published As

Publication number Publication date
NO942327L (en) 1994-08-17
JPH07502509A (en) 1995-03-16
NZ246473A (en) 1996-05-28
FI942935A0 (en) 1994-06-17
CA2125966A1 (en) 1993-06-24
EP0618923A1 (en) 1994-10-12
FI942935A (en) 1994-07-27
WO1993012129A1 (en) 1993-06-24
ZA929764B (en) 1993-10-13
AU3325493A (en) 1993-07-19
EP0618923A4 (en) 1998-05-20
NO942327D0 (en) 1994-06-17
AU7032596A (en) 1997-01-16

Similar Documents

Publication Publication Date Title
MX9207334A (en) NUCLEIC ACIDS PEPTIDICS AND PHARMACEUTICAL FORMULATION CONTAINING THEM
ES2163444T3 (en) COMPOSITIONS AND METHODS FOR THE ORAL ADMINISTRATION OF PHARMACOS.
BR9405798A (en) Methods for in vivo release of biological material and useful compositions thereof
ES2075011T3 (en) USE OF GAMMA-HYDROXYBUTRIC ACID SALTS TO PREPARE PHARMACEUTICAL COMPOSITIONS FOR USE IN THE TREATMENT OF ALCOHOLISM, AND THE COMPOSITIONS OBTAINED.
PT96068A (en) PROCESS FOR THE PRODUCTION OF BIOLOGICALLY ACTIVE PROTEINS
SV1999000049A (en) NEW DIETHYDROPYRIMIDINES 2 HETEROCICLICAMENTE SUBSTITUTED REF. READ 32793-SV
ES2150496T3 (en) CONDENSED CYCLLOALKYLIMIDAZOPYRIDIDS.
DE58905028D1 (en) PHARMACEUTICAL COMBINATION PRODUCTS AND THE USE THEREOF AS AN ANTINEOPLASTIC MEDICINAL PRODUCT.
ES2122076T3 (en) DERIVATIVES OF NOR-BILIAR ACIDS, PROCEDURE FOR THE PREPARATION AND USE OF THESE COMPOUNDS AS MEDICINES.
MX9206851A (en) ORGANIC SALTS OF N, N'-DIACETIL CYSTINE, PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM.
DE68908456T2 (en) Drug delivery matrix.
PT689550E (en) ANTIMICROBIAL PEPTIDES OF BOVINE NEUTROPHILS
ES2141229T3 (en) PHARMACEUTICAL PRODUCTS OF MODIFIED PROTEINS AND PEPTIDES.
AR006569A1 (en) DERIVATIVES OF CARBOXYLIC ACIDS, MEDICINES CONTAINING THESE COMPOUNDS, THEIR USE AND PROCEDURES FOR THEIR PREPARATION
PT749317E (en) THERAPEUTIC APPLICATIONS OF DIMERIC PRODUCTS OF PERMEABILITY INDUCED BACTERICID PROTEINS
ES2178048T3 (en) USE OF RIFAXIMINE AS A MEDICINAL PRODUCT FOR THE TREATMENT OF DIARRHEA BY CRYPTOSPORIDIOSIS.
DE3770280D1 (en) PHARMACEUTICAL PREPARATIONS FOR STABILIZING INTERFERON ALPHA.
AR024742A1 (en) CYCLOPEPTIDIC DERIVATIVES THAT ACT AS INHIBITORS OF THE INTEGRIN ALFA v BETA 6, THE MEDICINES BASED ON THESE COMPOUNDS, THE PHARMACEUTICAL COMPOSITIONS CONTAINING AT LEAST ONE OF THESE MEDICATIONS, AND THE USE OF THESE PERMITTED PREPARATIONS.
DE69900756D1 (en) USE OF HMG PROTEINS FOR THE PRODUCTION OF MEDICINAL PRODUCTS WITH CYTOTOXIC EFFECT
ES2240971T3 (en) TUMOR SUPPRESSING GENES, PROTEINS CODED BY THEM AND USE OF SUCH GENES AND PROTEINS.
PT81345B (en) METHOD FOR PREPARING NEW ACTIVE PEPTIDEES ON THE CENTRAL NERVOUS SYSTEM WITH ACTION ON THE COLINERGIC SYSTEM, AND OF PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS
ES2058988T3 (en) PREPARATION OF MEDICINES FOR THE SYSTEMIC TREATMENT OF ORNAMENTAL AND USEFUL FISH.
ES2068893T3 (en) NEW PEPTIDES, THEIR USE AS IMMUNO-SUPPRESSANTS AND PROCEDURES FOR ITS PREPARATION.
ES2032582T3 (en) PROCEDURE FOR PREPARING DERIVATIVES OF THE OXIME OF 1,2,5,6, -TETRAHIDROPIRIDIN -3-CARBOXIALDEHYDE.
AR005750A1 (en) PHARMACEUTICAL COMPOSITION TO TREAT OR PREVENT ZOSTER INFECTIONS IN PERSONS INFECTED WITH THE VARICELA ZOSTER VIRUS AND PROCEDURE FOR PREPARING SUCH COMPOSITION